Efficacy of cisplatin plus vinorelbine adjuvant chemotherapy with split‑dose administration of cisplatin after complete resection of stage II‑IIIA non‑small cell lung cancer

Funaguchi,Norihiko; Iihara,Hirotoshi; Kaito,Daizo; Gomyo,Takenori; Sasaki,Yuka; Yanase,Komei; Endo,Junki; Ito,Fumitaka; Hirose,Chiemi; Ohno,Yasushi; Okura,Hiroyuki

doi:10.3892/mco.2022.2509

Efficacy of cisplatin plus vinorelbine adjuvant chemotherapy with split‑dose administration of cisplatin after complete resection of stage II‑IIIA non‑small cell lung cancer

Authors:
- Norihiko Funaguchi
- Hirotoshi Iihara
- Daizo Kaito
- Takenori Gomyo
- Yuka Sasaki
- Komei Yanase
- Junki Endo
- Fumitaka Ito
- Chiemi Hirose
- Yasushi Ohno
- Hiroyuki Okura
View Affiliations

Affiliations: Department of Cardiology and Respiratory Medicine, Gifu University Graduate School of Medicine, Gifu 501‑1194, Japan, Department of Pharmacy, Gifu University Hospital, Gifu 501‑1194, Japan
Published online on: February 7, 2022 https://doi.org/10.3892/mco.2022.2509
Article Number: 76

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Although co‑administration of cisplatin (CDDP) and vinorelbine (VNR) has been established as a standard of care adjuvant chemotherapy for non‑small cell lung cancer (NSCLC), there is a lack of clinical data on its safety and efficacy in Japanese patients receiving split‑dose administration of CDDP. The present study analyzed patients who received CDDP + VNR with split‑dose administration of CDDP after undergoing complete resection of NSCLC. Patients received four courses of CDDP (40 mg/m²) and VNR (25 mg/m²) on days 1 and 8, every 3 weeks. There were 27 male and 13 female patients; the mean age was 65 years (range 38‑78 years), the postoperative disease staging distribution was IIA/IIB/IIIA: 14/8/18 patients, and histological distribution was adenocarcinoma/squamous cell carcinoma/others: 24/12/4 patients, respectively. Of the 40 patients, 28 (70%) completed the four courses of treatment. The mean total dose administered was 279 mg/m² CDDP (87.2%) and 172 mg/m² VNR (86%). The major adverse events included Grade (G) 3 or higher neutropenia (80%), G3 phlebitis (5%) and vomiting (2.5%). There was no G2 or higher serum creatinine level elevation, G3 or higher anorexia and nausea, or any treatment‑related deaths. The overall completion rate of four courses was 70 and 62.5% for patients aged 70 years and older, whereas the overall percentage of patients that could complete three or more courses was 85 and 87.5% for patients aged 70 years and older. The relapse‑free survival rate was 60% at 3 years and 57.5% at 5 years. Overall survival rate was 80% at 3 years and 60% at 5 years. The present study demonstrated the sufficient tolerability, safety and efficacy of combined CDDP + VNR adjuvant chemotherapy with split‑dose administration of CDDP, with a low risk of gastrointestinal toxicities or nephrotoxicity.

View Figures

View References

1	Sawabata N, Miyaoka E, Asamura H, Nakanishi Y, Eguchi K, Mori M, Nomori H, Fujii Y, Okumura M, Yokoi K, et al: Japanese lung cancer registry study of 11,663 surgical cases in 2004: Demographic and prognosis changes over decade. J Thorac Oncol. 6:1229–1235. 2011.PubMed/NCBI View Article : Google Scholar
2	Chemotherapy in non-small cell lung cancer. A meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ. 311:899–909. 1995.PubMed/NCBI
3	Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP and Vansteenkiste J: International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med. 350:351–360. 2004.PubMed/NCBI View Article : Google Scholar
4	Winton T, Livingston R, Johnson D, Rigas J, Johnston M, Butts C, Cormier Y, Goss G, Inculet R, Vallieres E, et al: Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med. 352:2589–2597. 2005.PubMed/NCBI View Article : Google Scholar
5	Douillard JY, Rosell R, De Lena M, Carpagnano F, Ramlau R, Gonzáles-Larriba JL, Grodzki T, Pereira JR, Le Groumellec A, Lorusso V, et al: Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant navelbine international trialist association [ANITA]): A randomised controlled trial. Lancet Oncol. 7:719–727. 2006.PubMed/NCBI View Article : Google Scholar
6	Butts CA, Ding K, Seymour L, Twumasi-Ankrah P, Graham B, Gandara D, Johnson DH, Kesler KA, Green M, Vincent M, et al: Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: Updated survival analysis of JBR-10. J Clin Oncol. 28:29–34. 2010.PubMed/NCBI View Article : Google Scholar
7	Bennouna J, Senellart H, Hiret S, Vaissiere N and Douillard JY: Impact of histology on survival of resected non-small cell lung cancer (NSCLC) receiving adjuvant chemotherapy: Subgroup analysis of the adjuvant vinorelbine (NVB) cisplatin (CDDP) versus observation in the ANITA trial. Lung Cancer. 74:30–34. 2011.PubMed/NCBI View Article : Google Scholar
8	Pignon JP, Tribodet H, Scagliotti GV, Douillard JY, Shepherd FA, Stephens RJ, Dunant A, Torri V, Rosell R, Seymour L, et al: Lung adjuvant cisplatin evaluation: A pooled analysis by the LACE Collaborative Group. J Clin Oncol. 26:3552–3559. 2008.PubMed/NCBI View Article : Google Scholar
9	Douillard JY, Tribodet H, Aubert D, Shepherd FA, Rosell R, Ding K, Veillard AS, Seymour L, Le Chevalier T, Spiro S, et al: Adjuvant cisplatin and vinorelbine for completely resected non-small cell lung cancer: Subgroup analysis of the lung adjuvant cisplatin evaluation. J Thorac Oncol. 5:220–228. 2010.PubMed/NCBI View Article : Google Scholar
10	Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac LR, D'Amico TA, et al: NCCN guidelines insights: Non-small cell lung cancer, version 2.2021. J Natl Compr Canc Netw. 19:254–266. 2021.PubMed/NCBI View Article : Google Scholar
11	Yamaguchi M, Takeo S, Suemitsu R and Matsuzawa H: Feasibility study for biweekly administration of cisplatin plus gemcitabine as adjuvant-chemotherapy for completely resected non-small cell lung cancer. Cancer Chemother Pharmacol. 66:107–112. 2010.PubMed/NCBI View Article : Google Scholar
12	Ohe Y, Ohashi Y, Kubota K, Tamura T, Nakagawa K, Negoro S, Nishiwaki Y, Saijo N, Ariyoshi Y and Fukuoka M: Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm cooperative study in Japan. Ann Oncol. 18:317–323. 2007.PubMed/NCBI View Article : Google Scholar
13	Kenmotsu H, Yamamoto N, Yamanaka T, Yoshiya K, Takahashi T, Ueno T, Goto K, Daga H, Ikeda N, Sugio K, et al: Randomized phase III study of pemetrexed plus cisplatin versus vinorelbine plus cisplatin for completely resected stage II to IIIA nonsquamous non-small-cell lung cancer. J Clin Oncol. 38:2187–2196. 2020.PubMed/NCBI View Article : Google Scholar
14	Kenmotsu H, Ohde Y, Wakuda K, Nakashima K, Omori S, Ono A, Naito T, Murakami H, Kojima H, Takahashi S, et al: Survival data for postoperative adjuvant chemotherapy comprising cisplatin plus vinorelbine after complete resection of non-small cell lung cancer. Cancer Chemother Pharmacol. 80:609–614. 2017.PubMed/NCBI View Article : Google Scholar
15	Furukawa N, Kawaguchi R and Kobayashi H: Use of high-dose cisplatin with aprepitant in an outpatient setting. Eur J Cancer Care (Engl). 21:436–441. 2012.PubMed/NCBI View Article : Google Scholar
16	Sonobe M, Okubo K, Teramukai S, Yanagihara K, Sato M, Sato T, Chen F, Sato K, Fujinaga T, Shoji T, et al: Phase II study of adjuvant vinorelbine and cisplatin in Japanese patients with completely resected stage II and III non-small cell lung cancer. Cancer Chemother Pharmacol. 74:1199–1206. 2014.PubMed/NCBI View Article : Google Scholar
17	Ng TL, Hutton B and Clemons M: Chemotherapy-induced nausea and vomiting: Time for more emphasis on nausea? Oncologist. 20:576–583. 2015.PubMed/NCBI View Article : Google Scholar
18	Takiguchi Y, Moriya T, Asaka-Amano Y, Kawashima T, Kurosu K, Tada Y, Nagao K and Kuriyama T: Phase II study of weekly irinotecan and cisplatin for refractory or recurrent non-small cell lung cancer. Lung Cancer. 58:253–259. 2007.PubMed/NCBI View Article : Google Scholar
19	Ozawa Y, Inui N, Naitoh T, Yasuda K, Nagayama M, Shirai T, Suganuma H, Fujii M, Nakamura H, Suda T and Chida K: Phase II study of combination chemotherapy with S-1 and weekly cisplatin in patients with previously untreated advanced non-small cell lung cancer. Lung Cancer. 63:68–71. 2009.PubMed/NCBI View Article : Google Scholar
20	Hiramatsu A, Iwasaki Y, Koyama Y, Tamiya N, Hosogi S, Nakanishi M, Kohno Y, Ueda M, Arimoto T and Marunaka Y: Phase II trial of weekly gemcitabine and split-dose cisplatin for advanced non-small-cell lung cancer. Jpn J Clin Oncol. 39:779–783. 2009.PubMed/NCBI View Article : Google Scholar
21	Berardi R, Porfiri E, Scartozzi M, Lippe P, Silva RR, Nacciarriti D, Menichetti ET, Tummarello D, Carle F, Piga A and Cellerino R: Elderly patients with advanced non-small cell lung cancer: A phase II study with weekly cisplatin and gemcitabine. Oncology. 65:198–203. 2003.PubMed/NCBI View Article : Google Scholar
22	Horinouchi H, Kubota K, Itani H, Taniyama TK, Nakamichi S, Wakui H, Kanda S, Nokihara H, Yamamoto N, Sekine I and Tamura T: Short hydration in chemotherapy containing cisplatin (≥75 mg/m2) for patients with lung cancer: A prospective study. Jpn J Clin Oncol. 43:1105–1109. 2013.PubMed/NCBI View Article : Google Scholar